ArticleBMC cancer2023
Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors.Annals of medicine · 2025Pooled it
- Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer.Journal for immunotherapy of cancer · 2026Article
- AptoDetect™-Lung Assay as a Blood-Based Predictor of Advanced-Stage Lung Cancer in Patients with Lung-RADS 3-4 Pulmonary Nodules: A Multicenter Prospective Cohort Study.Biomedicines · 2026Article
- Prediction model incorporating dynamic changes in serum tumor markers for evaluating the efficacy of neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study.European journal of medical research · 2025Article
- A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small-cell lung cancer.The oncologist · 2025Article
- Dynamic variations in peripheral blood indices and their association with efficacy and adverse reactions of pd- 1 inhibitor combined chemotherapy in patients with advanced gastric cancer.BMC gastroenterology · 2025Article
- Efficacy and safety of immunotherapy in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: a multicenter retrospective study.Therapeutic advances in medical oncology · 2025Article
- Prognostic value of immunoinflammatory indicators and tumor markers for first-line chemotherapy in patients with non-small cell lung cancer.American journal of cancer research · 2025Article
- Prediction of immunotherapy efficacy for pulmonary lymphoepithelioma-like carcinoma using baseline routine blood tests and serum tumor markers: a multicenter retrospective study.Therapeutic advances in medical oncology · 2025Article
- Investigation of Programmed Death Ligand-1 as a New Prognostic Biomarker in Pancreatic Cancer Patients.ACS pharmacology & translational science · 2024Article
- Construction of a pathomics model for predicting mRNAsi in lung adenocarcinoma and exploration of biological mechanism.Heliyon · 2024Article
- Diagnostic value of microRNA-200 expression in peripheral blood-derived extracellular vesicles in early-stage non-small cell lung cancer.Clinical and experimental medicine · 2024Article
- Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer.BMC cancer · 2024Article
- Clinical Applications of Comprehensive Genomic Profiling in Advanced Non-Small-Cell Lung Cancer-A Case Series.Current oncology (Toronto, Ont.) · 2024Article
- The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma.Frontiers in oncology · 2024Article
- Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study.Frontiers in immunology · 2024Article
- Prognostic role of serum carcinoembryonic antigen in patients receiving liver resection for colorectal cancer liver metastasis: A meta-analysis.World journal of gastrointestinal surgery · 2023Article
- POLE: Development and Validation of a Pulmonary Embolism Prediction Model in Lung Cancer.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the association between baseline serum tumor markers (STMs) (carcinoembryonic antigen [CEA], neuron-specific enolase [NSE], cytokeratin-19 fragment [CYFRA21-1], carbohydrate antigen 19-9 [CA19-9], and carbohydrate antigen 125 [CA125]) and the efficacy of first-line immunotherapy in patients with advanced non-small cell lung cancer.
methodsThis multicenter retrospective study evaluated patients who received first-line immunotherapy between July 2017 and July 2022. The endpoints were progression-free survival (PFS) and overall survival (OS), as defined by the Response Evaluation Criteria in Solid Tumors version 1.1. We divided the patients into three groups based on STM levels: Group A ≥ threefold upper limit of normal, threefold upper limit of normal > Group B > upper limit of normal, and Group C ≤ upper limit of normal.
resultsIn total, 716 patients were included in this study. In Cox proportional hazards analyses, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung adenocarcinoma (LUAD). Except for CA19-9 level, the STM levels in Group C were independently associated with superior PFS and OS in patients with lung squamous carcinoma (LUSC). Except for CEA and CA19-9 levels, the levels in Group A were independently associated with inferior PFS and OS in patients with LUAD and LUSC.
conclusionsSerum CEA, NSE, CYFRA21-1, and CA125 levels can predict PFS and OS in patients with LUAD and LUSC, and serum CA19-9 levels can predict PFS and OS in patients with LUAD. The higher the serum NSE, CYFRA21-1, and CA125 levels, the worse the PFS and OS in patients with LUAD and LUSC. In addition, the higher the serum CA19-9 level, the worse the OS in patients with LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.